文献类型：期刊文献

中文题名：重组人骨形态发生蛋白2诱导骨修复的应用及前景

英文题名：Recombinant human bone morphogenetic protein-2 induces bone repair

作者：谢兴文[1];姜徽[2];李宁[2];李盛华[3];宋敏[2];赵永利[2];侯费祎[2];黄晋[2]

第一作者：谢兴文

机构：[1]甘肃省中医药研究院骨伤病研究所,甘肃省兰州市730050;[2]甘肃中医学院,甘肃省兰州市730020;[3]甘肃省中医院,甘肃省兰州市730050

第一机构：甘肃省中医药研究院骨伤病研究所,甘肃省兰州市730050

年份：2013

卷号：17

期号：7

起止页码：1319

中文期刊名：中国组织工程研究

外文期刊名：Chinese Journal of Tissue Engineering Research

收录：CSTPCD;;Scopus;CSCD:【CSCD_E2013_2014】；

基金：国家自然科学基金项目(81060299)~~

语种：中文

中文关键词：组织构建;组织构建学术探讨;重组人骨形态发生蛋白2;骨组织工程;骨修复;生物相容性;载体;细胞生长因子;国家自然科学基金

外文关键词：tissue construction; academic discussion of tissue construction; recombinant human bonemorphogenetic protein-2; bone tissue engineering; bone repair; biocompatibility; carrier; cell growth factors; theNational Natural Science Foundation of China

摘要：背景:重组人骨形态发生蛋白2具备诱导成骨时间更早、成骨量较天然骨形态发生蛋白2多、生物学活性好、生物相容性好、成本低等特点,已成为近年来临床骨科创伤疾病防治研究的热点。目的:总结重组人骨形态发生蛋白2在骨组织工程及骨修复领域应用中的优势、不足及目前国内外的研究进展。方法:经第一作者检索CNKI数据库及SPRINGERLINK数据库2005至2011年与重组人骨形态发生蛋白2在诱导骨再生、骨组织修复有关研究进展方面的文献,英文检索词为"rhBMP-2,bone tissue engineering,bone repair materials",中文检索词为"重组人骨形态发生蛋白2,骨组织工程,骨修复"。共检索出98篇,最终保留30篇进行归纳总结。结果与结论:骨骼内天然骨形态发生蛋白2含量稀少、提取成本高昂,临床应用严重受限。重组人骨形态发生蛋白2有显著的成骨诱导能力,在骨组织工程及骨修复领域展现了巨大的潜在应用价值。体外试验无细胞毒性具有良好的生物相容性可供临床应用,其中重组人骨形态发生蛋白2和重组人骨形态发生蛋白7现已被应用于外科整形手术诱导骨再生,但由于重组人骨形态发生蛋白2是外源性细胞生长因子,临床应用多为超生理剂量,故潜在有软组织水肿,皮肤红疹、局部炎症反应、异位骨化和免疫反应等不良后果的危险,所以重组人骨形态发生蛋白2用于人体后的安全性研究还须长期密切关注。找到理想的载体,有效控制其在体内缓释是重组人骨形态发生蛋白2应用研究的关键问题。
BACKGROUND： Recombinant human bone morphogenetic protein-2 has better biological activity, lower cost, better biocompatibility and earlier osteoinductive time than natural bone morphogenetic protein-2, which has become a hot topic on clinical orthopedic trauma disease prevention and treatment in recent years. OBJECTIVE： To make a consumption of the advantages, disadvantages and the future development of recombinant human bone morphogenetic protein-2 in bone tissue engineering and bone repair. METHODS： The first author searched CNKI and SPRINGERLINK （2005/2011） to retrieve the articles about the recent development of recombinant human bone morphogenetic pretein-2 on bone tissue engineering and bone repair. The key words were ＂rhBMP-2, bone tissue engineering, bone repair materials＂ in Chinese and English, respectively. Totally 98 articles were searched, and finally 30 articles were retained to make a further research. RESULTS AND CONCLUSION： The content of natural human bone morphogenetic protein-2 is very low and the cost of gaining is high. This, to some extent, limits its clinical usage. However, recombinant human bone morphogenetic protein-2 overcomes this disadvantage, and shows its great potential in bone tissue engineering and bone repair. According to the in vitro tests, it has good biocompatibility and no cytotoxicity for clinical application. Recombinant human bone morphogenetic protein-2 and recombinant human bone morphogenetic prctein-7 have now been applied to plastic surgery to induce bone regeneration. Because recombinant human bone morphogenetic protein-2 is an exogenous cell growth factor, its clinical application often relays on multi-super-physiological doses, leading to a series of potential risks, such as, soft tissue edema, skin rash, and local inflammatory reaction, heterotopic ossification and immune response. Therefore, the safety studies of recombinant human bone morphogenetic protein-2 for the human body need to be researched in long run. It is the core issue to find an ideal carder for the effective control of in vivo sustained release of recombinant human bone morphogenetic protein-2.